NCT00371761View on ClinicalTrials.gov

PegIntron Versus Adefovir in the Treatment of Chronic Hepatitis B (CHB) e Antigen Positive Patients in Taiwan (P04498/MK-4031-278)

PHASE3CompletedINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

September 30, 2006

Primary Completion Date

February 28, 2009

Study Completion Date

February 28, 2009

Conditions
Hepatitis B, Chronic (CHB)
Interventions
BIOLOGICAL

Pegylated interferon alfa-2b (PegIntron)

Powder for injection in vials ( 100, and 120 microgram strengths), subcutaneous, dose of 1.5 micrograms/kg, weekly for up to 24 weeks

DRUG

Adefovir dipivoxil (adefovir)

10 mg adefovir dipivoxil (equivalent to 5.4.5 mg adefovir) tablets, oral, dose of 1 tablet per day for up to 48 weeks

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT00371761 - PegIntron Versus Adefovir in the Treatment of Chronic Hepatitis B (CHB) e Antigen Positive Patients in Taiwan (P04498/MK-4031-278) | Biotech Hunter | Biotech Hunter